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Abstract
Ribose-based nucleoside 5′-diphosphates and triphosphates and related nucleotides were compared
in their potency at the P2Y receptors with the corresponding nucleoside 5′-phosphonate derivatives.
Phosphonate derivatives of UTP and ATP activated the P2Y2 receptor but were inactive or weakly
active at P2Y4 receptors. Uridine 5′-(diphospho)phosphonate was approximately as potent at the
P2Y2 receptor as at the UDP-activated P2Y6 receptor. These results suggest that removal of the 5′-
oxygen atom from nucleotide agonist derivatives reduces but does not prevent interaction with the
P2Y2 receptor. Uridine 5′-(phospho)phosphonate as well as the 5′-methylphosphonate equivalent of
UMP were inactive at the P2Y4 receptor and exhibited maximal effects at the P2Y2 receptor that
were ≤50% of that of UTP suggesting novel action of these analogues.
The P2Y receptors are a family of eight G protein-coupled receptors (GPCRs) of class A that
respond to diverse nucleotides.1 The human P2Y1, P2Y12, and P2Y13 receptors are activated
preferentially by ADP, while the human P2Y11 receptor is activated preferentially by ATP.
The human P2Y4, P2Y6, and P2Y14 subtypes respond exclusively to various uracil nucleotides,
and the human P2Y2 receptor responds to both UTP and ATP. Depending on the subtype, the
effector coupling of these receptors is typically through Gq or Gi proteins, to stimulate
phospholipase or to inhibit of adenylate cyclase, respectively.
P2Y receptors are targets for therapeutic approaches, some of which are currently being
explored at an early stage.2 Several clinical applications of P2Y receptor ligands are more
advanced, such as P2Y12 receptor antagonists as antithrombotic agents3 and P2Y2 receptor
agonists as drugs for cystic fibrosis and dry eye disease.4
To aid in the design of P2Y receptor ligands, we have reported rhodopsin-based molecular
models of all known subtypes of P2Y receptors.5,6 Various amino acid residues have been
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proposed to coordinate the bound nucleotide ligands in P2Y1 receptors and other P2Y subtypes.
The medicinal chemistry of P2Y receptors that are responsive to uracil nucleotides has recently
been explored.7–11 The conformational constraint or replacement of the hydroxyl moieties of
the ribose moiety have been introduced as a means for increasing the selectivity at P2Y1,
P2Y2, or P2Y6 receptors.12,13
In the present study, we have explored the removal of the 5′-oxygen or its replacement by
carbon moieties, resulting in 5′-phosphonate derivatives. The activity of various phosphonate
derivatives was compared with the native ribosides at various P2Y receptor subtypes. Potency
was best preserved at the P2Y2 receptor following this modification. However, the apparent
efficacy of activation of the P2Y2 receptor by several phosphonate derivatives was variable
and significantly less than 100%, suggesting a potential change in the mode of interaction with
the receptor. The introduction of the phosphonate linkage is also intended to increase stability
of the alpha-phosphate toward hydrolysis by nucleotidases, which is frequently a limitation in
the pharmacological use of nucleotide derivatives in in vitro and in vivo experiments.
Various adenine and uracil nucleotide phosphonate derivatives were synthesized and evaluated
in functional assays of different P2Y receptors (Table 1). The derivatives in which the 5′-
oxygen was omitted, i.e., 1, 2, and 4–6, were prepared by known synthetic routes.14 The
synthetic route to the elongated 5′-phosphonate derivatives 3 and 7 is shown in Scheme 1
following earlier reported strategies.15,19 5′, 6′-Vinyl phosphonate 9 was synthesized by
oxidation of 2′, 3′-O-isopropylideneuridine (8) to the 5′-aldehyde intermediate, which was
immediately reacted with freshly prepared [(diethoxyphosphinyl)methylidene]
triphenylphosphorane.16 The E-configuration of the resulting alkene could be inferred from
the large coupling constant (3J = 17.3 Hz). Catalytic hydrogenation of the resulting vinyl
phosphonate ester 9 in the presence of palladium on carbon gave the corresponding saturated
phosphonate ester 10. Simultaneous deprotection of the phosphonate diester and the acetonide
was achieved upon treatment with TMSBr, yielding the corresponding 5′-phosphonate 7.
To prepare the (diphospho)phosphonate derivative 3, vinyl phosphonate 11, obtained by
hydrolysis of both the phosphonate esters and the acetonide upon treatment with TMSBr,15
was activated with CDI in DMF, followed by the addition of bis(tri-n-butylammonium)
pyrophosphate.
For biological assays, the human P2Y1, P2Y2, P2Y4, and P2Y6 receptors, which are coupled
to activation of phospholipase C (PLC) through Gq, were stably expressed in 1321N1 human
astrocytoma cells, which lack a native response to nucleotides.17,18 Activity at the human
P2Y14 receptor was followed by quantification of phosphoinositide hydrolysis in COS-7 cells
coexpressing a phospholipase C-activating chimeric G protein, Gαq/i, which is activated by
Gi-coupled receptors.20 Concentration effect curves were generated for each of the
phosphonate derivatives at the relevant receptor(s), and the EC50 values were compared to the
potency of the corresponding nucleotide in the native riboside series (Table 1). Representative
data for the uridine 5′-(diphospho)phosphonate 2 and the vinylicdiphosphophosphonate 3 at
the P2Y2 receptor are illustrated in Fig. 1.
Full agonist activity was observed with 1, 2, and 3 at the P2Y2 receptor, although the potencies
were reduced by 16–176-fold relative to ATP or UTP. Although UTP is also a potent agonist
at the human P2Y4 receptor, neither uridine 5′-(diphospho)phosphonate 2, which is the simple
phosphonate equivalent of UTP, nor the vinyl phosphonate derivative 3 exhibited activity at
this receptor. Compounds 2 and 3 were inactive at the P2Y6 receptor. Uridine 5′-
phosphophosphonate 4, which is the simple phosphonate equivalent of UDP, was a full agonist
at the P2Y6 receptor exhibiting a potency approximately 40-fold less than UDP. In contrast,
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uridine 5′-(glucose-[1′]phospho)-phosphonate 6 exhibited no activity at the UDP-glucose
activated P2Y14 receptor.
A surprising result from our tests of activity was that uridine 5′-phosphophosphonate 4 was
essentially as potent for activation of the P2Y2 receptor as for activation of the P2Y6 receptor
and had no activity at the P2Y4 receptor. However, the maximal effect observed with 4 for
activation of the P2Y2 receptor was only ~50% of that observed with UTP (Fig. 2A). Although
UMP has no effect, uridine 5′-methylene-phosphonate 7 also was a relatively potent (EC50 =
1.6 ± 0.4 μM) agonist at the P2Y2 receptor. Similar to 4, the maximal effect observed at the
P2Y2 receptor with 7 was <50% of that observed with UTP (Fig. 2B). Analogue 7 had no effect
on the P2Y4 and P2Y6 receptors.
Preliminary experiments examining the capacity of high concentrations of compounds 4 and
7 to antagonize activation of the P2Y2 receptor by UTP failed to provide convincing evidence
that these molecules interact with the orthosteric binding site of the receptor. Therefore, these
novel analogues potentially activate the P2Y2 receptor through an allosteric mechanism.
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Activity of agonists 2 and 3 at P2Y2 receptors as indicated by activation of PLC in stably
transfected astrocytoma cells. The effect of UTP corresponds to 100%.
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Partial agonist activity of 4 (A) and 7 (B) at P2Y2 receptors as indicated by activation of PLC
in stably transfected astrocytoma cells. The effect of UTP corresponds to 100%.
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Reagents and conditions: (a) (i) IBX, CH3CN; (ii) (EtO)2P(O)C=PPh3, DMSO (44%); (b)
H2, Pd/C, MeOH (84%); (c) TMSBr, CH2Cl2 (62%); (d) Bu3N, CDI, DMF;
(Bu3NH)2H2P2O7; TEAB 1M (22%); (e) TMSBr, CH2Cl2 (65%).
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